The choice for oral anticoagulant (OAC) therapy was previously limited to the vitamin K antagonists (VKAs). The advent of the direct oral anticoagulants (DOACs) brought with it the expectation that oral anticoagulation would become simpler (with the elimination of routine monitoring and introduction of a fixed-dose anticoagulant), and that the use of VKAs would be slowly phased out. Although DOACs have made anticoagulation more convenient and accessible, we are now faced with what can be described as a tyranny of choice, together with many unanswered questions relating to DOAC use. These include optimal DOAC selection and dosing, use in complex 'real-world' patients, the role for monitoring and issues surrounding adherence. Warfarin remains the anticoagulant of choice in certain scenarios (e.g. metallic heart valves). The future holds much excitement: clinical studies are underway to expand the indications for DOACs and experience continues to grow outside the trials setting.
For many years, the only oral anticoagulants (OACs) available world-wide were the vitamin K antagonists (VKAs) (Johnson et al, 2016) , of which warfarin is the most commonly prescribed in the United Kingdom (Protty & Hayes, 2017) . The direct oral anticoagulants (DOACs) offer an attractive alternative to VKAs and have a number of advantages, including: (i) no requirement for routine monitoring, (ii) fixed dosing, (iii) more predictable dose responses, (iv) no food interactions, and (v) fewer drug interactions (Baglin, 2013) . There are four DOACs available in the UK, with differing characteristics, and determining which DOAC and at what dose is the best choice for an individual patient with multiple co-morbidities can be difficult, particularly in complex 'real-world' patients who are under-represented in clinical trials. Evidence-based use for additional indications is increasing (e.g. rivaroxaban for acute coronary syndrome (ACS)), along with experience of DOACs outside the clinical trial setting. The utility of performing DOAC drug levels remains controversial but the lack of routine monitoring means that mechanisms to promote optimal adherence and persistence need consideration. Once termed 'new' or 'novel', DOAC use is now widespread and recognised as a cost-effective alternative to VKAs, e.g. in outpatient venous thromboembolism (VTE) treatment pathways (Coleman et al, 2017) .
Overview of currently approved DOACs and their licensed indications
There are four DOACs currently available in the UK: dabigatran, rivaroxaban, apixaban and edoxaban. All are National Institute for Clinical Excellence (NICE) approved but only for specific indications. An overview of these and the year in which they were approved for each indication (along with the relevant NICE technology appraisal) is provided in Table I .
Although DOACs share many similarities (including rapid onset of action and similar half-life) and are used for overlapping indications, there are a number of ways in which the DOACs differ. These mainly relate to posology and interaction profile and are summarised in Table II. A tyranny of choice -current challenges
Optimal selection of drug
As summarised in Table II , the DOACs differ in a number of ways. DOAC selection, therefore, requires consideration of the particular characteristics of each patient and drug, as well as patient choice. There are no randomised head-to-head trials of DOACs. All comparisons made are indirect and obfuscated by the trials' differing inclusion criteria and varying patient risk profiles. The DOACs have safety and efficacy comparable to VKAs and have consistently demonstrated a clinically relevant reduced risk (over 50%) of spontaneous intracranial bleeding (Raschi et al, 2016) .
Patients with a history of gastrointestinal (GI) bleeding
Although GI bleeding is common to all anticoagulants, the incidence of major GI bleeding varied among the four DOACs in clinical trials. In the non-valvular atrial fibrillation (NVAF) population, dabigatran 150 mg twice daily was associated with an increased risk of major GI bleeding compared to warfarin (1Á51 vs. 1Á02 %/year, P < 0Á001; relative risk (RR) 1Á5, 95% CI 1Á19-1Á89) in the RE-LY trial, while the major GI bleeding risk was comparable to warfarin for dabigatran 110 mg twice daily (1Á12 vs. 1Á02 %/year, P = 0Á43; RR 1Á1, 95% CI 0Á86-1Á41) (Connolly et al, 2009 ). In the ROCKET-atrial fibrillation (AF) trial, rivaroxaban was associated with an increased rate of major and non-major GI bleeding compared to warfarin (3Á61 events/100 patient-years vs. 2Á60 events/100 patient-years, hazard ratio (HR 1Á42), 95% CI 1Á22-1Á66) (Sherwood et al, 2015) . In ARISTOTLE, no significant difference in the rate of major GI bleeding was noted between the apixaban (5 mg twice daily) and warfarin groups (Granger et al, 2011) . The annualised rate of major GI bleeding in ENGAGE-Thrombolysis In Myocardial Infarction (TIMI)-AF 48 was increased with edoxaban 60 mg daily compared to warfarin (1Á51% vs. 1Á23%, P = 0Á03, HR 1Á23, 95% CI 1Á02-1Á5) but was lowest with low-dose edoxaban (0Á82%, P < 0Á001, HR 0Á67, 95% CI 0Á53-0Á83) without loss in efficacy (Giugliano et al, 2013) . As comparisons between DOACs continue to be indirect, robust conclusions cannot be made. The risk profiles of patients in the original trials varied; the mean CHADS 2 (congestive heat failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke, transient ischaemic attack or thromboembolism) score was 2Á1 in RE-LY (Connolly et al, 2009 ) and ARISTOTLE (Granger et al, 2011) , 2Á8 in ENGAGE TIMI-AF 48 (Giugliano et al, 2013) and 3Á5 in ROCKET-AF (Patel et al, 2011) . Several of the risk factors in the stroke risk scores and haemorrhage risk scores overlap and higher CHADS 2 (and CHA 2 DS 2 -VASc; CHADS 2 + vascular disease, age 65-74 years, sex category) scores are associated with increased haemorrhage risk on anticoagulation (Quinn et al, 2016) . Despite apixaban generally being considered to have a more favourable GI bleeding risk profile, in ARISTOTLE, the most frequent site of haemorrhage on apixaban was still GI (31%) and although there were fewer GI haemorrhage events on apixaban, this did not reach statistical significance (Hylek et al, 2014) .
Real-world data examining rivaroxaban use have not confirmed an increased GI bleeding risk. In XANTUS (a realworld, prospective, observational study of patients treated with rivaroxaban for stroke prevention in AF) the incidence of major GI bleeding was 0Á9 events per 100 patient-years (Camm et al, 2016) . Although this appears reassuring, this is markedly lower than that reported in the randomised clinical trial and may partly be explained by appropriate patient selection as well as the recognised limitations of real-world data including under-/over-reporting of side effects.
Aside from DOAC selection, in order to reduce the risk of GI bleeding on anticoagulation, it is important to modify risk factors e.g. alcohol ingestion where possible. In ROCKET-AF, independent clinical factors most strongly associated with GI bleeding were baseline anaemia, history of GI bleeding and long-term aspirin use (Sherwood et al, 2015) . The need for concomitant aspirin should always be reviewed. Additional strategies include avoiding supra-therapeutic anticoagulation (by checking renal function and appropriate dosing), and encouraging patients to participate in national colon cancer screening (Desai et al, 2013) . Based on the current published data, our local practice is to generally use apixaban in patients with a history of gastrointestinal bleeding.
Specific reversal agents/'antidotes'
Dabigatran is currently the only DOAC with a licensed antidote. Idarucizumab, an antibody fragment designed specifically to bind to and neutralise dabigatran, has proven efficacy and safety as a specific reversal agent (Pollack et al, 2015) and was launched in the UK in December 2015 (https://www.nice.org.uk/advice/esnm73/chapter/Key-pointsfrom-the-evidence). There is no currently available antidote for the Xa-inhibitors at the time of writing, but preliminary data from the ANNEXA-4 trial using andexanet-alfa for the treatment of major bleeding on Xa-inhibitors has been published (Connolly et al, 2016) . Although this would provide a useful reversal agent for the gamut of Xa-inhibitors currently in clinical use, thrombotic events developed in 18% of patients within 30 days of follow-up (Connolly et al, 2016) and further data are awaited. While there is clearly a role for specific reversal agents (particularly if emergency surgery is required) and the availability of a reversal agent may influence DOAC choice, it should be noted that overall outcomes for bleeding events on DOACs, including mortality, have not been demonstrated to be worse than bleeding events occurring on warfarin and this applies to data from clinical trials (Majeed et al, 2013) as well as 'real-world' data from registries (Beyer-Westendorf et al, 2014) .
Optimal dose of selected drug
Clinical trials do not necessarily represent patients encountered in clinical practice and the exclusion of older patients with multiple co-morbidities from clinical trials is well documented (Tinetti, 2014) . Therefore, extrapolating data from clinical trials to such patients requires a degree of caution. Studies report that the lower doses of DOACs are frequently instituted without fulfilling the recommended dose-reduction criteria (Barra et al, 2016; Khan et al, 2016) and there is a valid concern of 'under-dosing'. Of note also, is the small proportion of patients in ARISTOTLE who received the lower dose of apixaban -just 4Á7% (Granger et al, 2011) . However, in certain cases, it is possible that using a lower dose may not be entirely inappropriate given some of the difficulties associated with the dose reduction recommendations and the lack of evidence in complex patients, e.g. the extremely elderly with multiple co-morbidities including anaemia, who would have been ineligible for the DOAC clinical trials.
Dose-reduction criteria
The dose reduction criteria differ for each drug and, confusingly, can differ for the same drug according to indication. For example, if rivaroxaban was being prescribed for stroke prevention in AF, for a patient with a creatinine clearance (CrCl) of 35 ml/min, the recommended dose according to prescribing criteria would be 15 mg daily (https://www.med icines.org.uk/emc/medicine/25586). If the same patient suffered an acute deep vein thrombosis (DVT), the recommended dosing would be 15 mg bd for 21 days following by a 20 mg daily maintenance dose (https://www.medicines.org. uk/emc/medicine/25586). Patients with a CrCl below 30 ml/ min were excluded from the acute DVT and continued treatment studies (Bauersachs et al, 2010) . The summary of product characteristics (SPC) states rather vaguely that: 'a dose reduction to 15 mg should be considered if the patients' assessed risk for bleeding outweighs the risk for recurrent DVT and PE' but also that 'the recommendation for the use of 15 mg is based on pharmacokinetic (PK) modelling and has not been studied in this clinical setting'. Clinicians are left with no clear guidelines and have to rely on experience and clinical judgement. The dose reduction criteria for apixaban in AF as per the ARISTOTLE trial, i.e. 2 or more of the following: age >80 years, weight <60 kg or serum creatinine >133 lmol/l (Granger et al, 2011) can result in seemingly unusual dosing recommendations. Applying these criteria to a 94-year-old lady, who weighs 61 kg with a creatinine of 90 lmol/l (CrCl 32 ml/min) would mean that she qualifies for the standard dose of apixaban i.e. 5 mg bd. The same criteria applied to a 40-year-old man, who weighs 59 kg and has a creatinine of 135 lmol/l (CrCl 54 ml/min) would mean he qualifies for the lower dose of 2Á5 mg bd. Similarly, for an 81-year-old with normal renal function, weighing 59Á9 kg or 60Á1 kg when attending the anticoagulation clinic will determine a 50% difference in anticoagulant dose. The SPC does specify that a dose reduction to 2Á5 mg bd should be instituted for patients with a CrCl of 15-29 ml/min (https://www.medicine s.org.uk/emc/medicine/27223) but this would not alter the above dosing conundrum. Ideally, the original trial would not have used an absolute creatinine level, as a criterion for dose reduction, but rather a CrCl cut-off, as has been the case with other DOAC trials.
It must be accepted that there will be expected difficulties when strict criteria are applied and that cut-offs are, by definition, absolute, however, it must also be realised that there is a real degree of uncertainty about the 'correct' dose in certain patients, particularly those who are 'borderline' for the dose-reduction criteria. In these 'borderline' patients there is a role for clinical judgement to influence dosing decisions. Perhaps, also, there is also a role for a drug level to guide optimal dosing.
Another group for whom there may be a role for a drug level is the very old, i.e. those >85 years. These patients were not well represented in the landmark DOAC trials and are increasingly been referred for anticoagulation therapy, particularly in the context of AF. A one-size fits all strategy risks under-/over-dosing as the very old are likely to have a degree of impaired renal and/or liver dysfunction, and so risk DOAC accumulation and potential bleeding. Chronological age by itself may not a good predictor of organ dysfunction and we suggest a shift in thinking from age to frailty. Frailty can be defined as a state of increased vulnerability resulting from ageing and associated with a decline in the body's physical and psychological reserves (British Geriatric Society, 2014) . It is thought that for a person classed as frail, a single change, such as a new medicine, will have a greater impact than if the person was in good health. Estimates suggest between 25% and 50% of people aged over 85 years are classed as frail (British Geriatric Society, 2014). Perhaps chronic frailty status would be a better covariate in determining dose adjustments in patients prescribed DOACs and we encourage researchers to report frailty status in future studies.
Extremes of body weight
Patients at extremes of weight represent another group for whom fixed dosing raises concerns. Obesity has long been recognised as a risk factor for developing VTE (Coon, 1977) but obese patients are frequently excluded from clinical trials and, while current guidelines suggest weight-based dosing of low molecular weight heparin (LMWH) without capping, there is limited published data on the use and efficacy of DOACs in extreme obesity (Ihaddadene & Carrier, 2016) . Only 14Á2% of patients weighed over 100 kg in the rivaroxaban arm of the EINSTEIN trial (Bauersachs et al, 2010) . A recent review of rivaroxaban management in relation to body weight and body mass index summarises the current data available from Phase I-III trials and concludes that standarddose rivaroxaban can be used safely in patients of all weight ranges (Uprichard, 2016) . A recently published UK study ) assessed the effect of extreme body weight and clinical outcomes with standard-dose rivaroxaban in VTE treatment. 167 patients were stratified into three weight-based groups (<50 kg, 50-120 kg, >120 kg), laboratory markers of rivaroxaban were measured 2-4 h post-dose and median follow-up was 14 months. Peak rivaroxaban Review ª 2017 John Wiley & Sons Ltd levels were significantly higher in patients with a lower body weight (<50 kg) but this did not impact on clinical outcomes. Patients who weighed >120 kg had comparable rivaroxaban levels to those of standard body weight. Although reassuring to some degree, further data are still required for those patients at the extreme end of the spectrum e.g. weight >140 kg or <40 kg before we can be assured that fixed doses of DOACs are appropriate. The Scientific & Standardisation Committee (SSC) of the International Society on Thrombosis & Haemostasis (ISTH) 2016 guidance on the use of DOACs in obese patients (Martin et al, 2016) recommends that: (i) appropriate standard dosing of DOACs is used in patients up to 40 kg/m 2 and weight 120 kg (for VTE prevention and treatment and prevention of ischaemic stroke and systemic arterial embolism in NVAF), (ii) DOACs should not be used in obese patients due to limited data and available PK/pharmacodynamic (PD) evidence suggesting decreased drug exposure, peak concentration and shorter elimination half-lives with increasing weight, and (iii) if DOACs are used in obese patients, to check drug-specific peak and trough levels. The guidance committee suggests that if the drug level is within the expected range, the DOAC can continue. However, if the drug level is below the expected range, changing to a VKA rather than adjusting the dose of the DOAC is recommended (Martin et al, 2016) .
Optimal dose for long-term secondary VTE prevention
As a result of the AMPLIFY-EXT trial (which compared two doses of apixaban (2Á5 mg and 5 mg twice daily) with placebo), apixaban 2Á5 mg twice daily is an option for extended anticoagulation for secondary VTE prevention. This is an attractive option given the low bleeding rates observed: the rates of major bleeding were 0Á2% in the 2Á5-mg apixaban group, and 0Á1% in the 5-mg apixaban group (Agnelli et al, 2013) , which rather curiously were even lower than those seen in the placebo group (0Á5%). In this trial, apixaban was compared to placebo, so it is not surprising that anticoagulation is more effective than no anticoagulation at reducing VTE. Furthermore, this was a group of essentially low-risk patients "for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy" (Agnelli et al, 2013) . It is not clear whether the low-dose apixaban strategy is as effective for patients considered at high-risk of VTE recurrence e.g. those with unprovoked massive PE, who would traditionally have remained on therapeutic anticoagulation with warfarin indefinitely. The three-arm EINSTEIN CHOICE trial investigated further the use of rivaroxaban in long-term secondary prevention, by comparing a reduced dose of rivaroxaban (10 mg once daily) with a standard dose (20 mg once daily) and with aspirin (100 mg/day) in patients with confirmed symptomatic VTE who have completed 6 or 12 months of anticoagulant treatment . The results found that rivaroxaban at either dose was more effective than aspirin in preventing recurrence, without a significant increase in the risk of major bleeding (Weitz et al, 2017) , and suggests an important role for the 10-mg rivaroxaban dose for the secondary prevention of VTE. The latest CHEST guidelines on antithrombotic therapy for VTE disease recognise the use of aspirin as an agent to reduce VTE recurrence (Kearon et al, 2016) . Although the guidelines do not recommend aspirin as an alternative to anticoagulation in those continuing with extended therapy, they suggest aspirin over no aspirin in those patients who decide to stop anticoagulants (Kearon et al, 2016) .
Cardiac indications for a DOAC

Atrial fibrillation with valvular heart disease
The DOACs are licensed for NVAF. All four pivotal trials excluded mechanical (metallic) prosthetic heart valves and the only published trial to evaluate a DOAC in this setting (the RE-ALIGN trial -where dabigatran was compared with warfarin) was terminated prematurely because of an excess of thromboembolic and bleeding events among patients in the dabigatran group . Warfarin, therefore, remains the anticoagulant of choice in patients with metallic heart valves. The CATHAR (Comparison of Antithrombotic Treatments After Aortic Valve Replacement) study (NCT02128841) has currently suspended participant recruitment awaiting interim analysis. This study was evaluating the use of rivaroxaban in patients after aortic mechanical valve replacement versus a historical control (VKA).
The inclusion criteria with respect to valvular lesions and (tissue) prosthetic valves were inconsistent in the DOAC AF trials, making it unclear what precisely was meant by 'nonvalvular' AF. For example, patients with bioprosthetic valves were included in ARISTOTLE and ENGAGE AF-TIMI 48 but excluded from RE-LY and ROCKET-AF. Subanalyses of the pivotal DOAC trials indicate that DOAC efficacy did not differ between patients with and without valvular heart disease (Di Biase, 2016). The definitions of NVAF have evolved over time (Di Biase, 2016) and the current consensus is that patients with AF and valvular heart disease excluding those with mechanical heart valves or moderate-severe mitral stenosis can be considered for a DOAC -this approach has been endorsed by the recent 2016 European Society of Cardiology (ESC) guidelines for the management of AF (Kirchhof, 2016) .
Atrial fibrillation in the setting of ischaemic heart disease
The increased bleeding risk associated with combining antiplatelet drugs with anticoagulation means that patients with ACS who are subsequently diagnosed with AF, or vice versa, require special consideration in order to treat both underlying conditions while trying to manage bleeding risk. The NICE guidelines for myocardial infarction (MI) published in November 2013, before widespread DOAC use (https://www. nice.org.uk/guidance/CG172) specifically state in the 'Do not do recommendations': "Do not add a new OAC (rivaroxaban, apixaban or dabigatran) in combination with dual antiplatelet therapy in people who otherwise need anticoagulation, who have had an MI".
AF with stable coronary artery disease
Recent ESC guidelines for the management of AF recommend that anticoagulated AF patients with stable vascular disease (no acute ischaemic events or coronary intervention in the preceding year) can be treated with anticoagulation monotherapy and concomitant antiplatelet therapy should not be prescribed (Kirchhof, 2016) . Adding aspirin to VKA does not reduce the risk of stroke or vascular events (including MI), but substantially increases bleeding events (So & Eckman, 2017) . Published data support the use of VKA for secondary prevention in patients with coronary artery disease, and VKA is at least as effective as aspirin (Kirchhof, 2016) .
AF with ACS and/or percutaneous coronary intervention (PCI)
The optimal combination of antithrombotic therapy or duration of combination therapy for AF patients undergoing PCI is not known but, in order to balance the bleeding risk, expert consensus recommends a short period (1-6 months) of 'triple therapy' (OAC, aspirin, clopidogrel), followed by a period (usually 12 months post ACS event) of dual therapy (OAC plus a single antiplatelet), then OAC alone (Kirchhof, 2016) . When a DOAC is used, the ESC guidelines recommend that the lowest dose effective for stroke prevention in AF should be considered and that dose reduction beyond the approved dosing tested in phase III trials is not currently recommended (Kirchhof, 2016) . In RE-LY and ENGAGE AF-TIMI 48 (where warfarin was compared with lower and higher doses of DOAC in a 1:1:1 ratio), the lower DOAC doses (dabigatran 110 mg bd and edoxaban 30 mg od) had proven non-inferiority compared to warfarin (Connolly et al, 2009; Giugliano et al, 2013) and therefore these appear to be reasonable options when considering an alternative to warfarin in triple therapy.
Since the ESC guidelines were published, the authors of the PIONEER ACS-AF trial suggested that rivaroxaban 2Á5 mg bd in combination with dual antiplatelet therapy (DAPT) may be an option for patients with AF who undergo PCI with stenting . 2124 patients were randomised to receive either low-dose rivaroxaban (15 mg once daily) plus a P2Y12 inhibitor for 12 months (Group 1), very-low-dose rivaroxaban (2Á5 mg twice daily) plus DAPT for 1, 6 or 12 months (Group 2), or standard therapy with a dose-adjusted VKA (once daily) plus DAPT for 1, 6, or 12 months (Group 3). The primary safety outcome was clinically significant bleeding, which was lower in the two groups receiving rivaroxaban than in the group receiving standard therapy. The rates of death from cardiovascular causes, MI, or stroke were similar in the three groups . However, the trial was designed primarily to look at bleeding rates and was not powered to examine stroke prevention per se. As such, the effectiveness of a 2Á5 mg bd rivaroxaban regimen at adequately reducing stroke risk remains uncertain. Importantly, DAPT comprised aspirin and clopidogrel in the vast majority of patients (93%) who received triple therapy, and therefore it should not be assumed that triple therapy in combination with ticagrelor/ prasugrel is equally safe.
Acute coronary syndrome
In the absence of AF, rivaroxaban is the only DOAC currently licensed for the treatment of ACS based on results from the ATLAS ACS 2-TIMI 51 trial (Mega et al, 2012) . This evaluated twice-daily rivaroxaban at doses of 2Á5 and 5 mg (compared with placebo) in addition to DAPT in patients with a recent ACS. Each dose reduced the primary efficacy end point (death from cardiovascular causes, MI or stroke, as compared with placebo), however, the 2Á5-mg dose of rivaroxaban, as compared with placebo, reduced the risk of death from cardiovascular causes and the risk of death from any cause while the 5-mg dose of rivaroxaban did not. Both doses significantly increased the rate for TIMI major bleeding (not related to coronary artery bypass graft (CABG)) compared with placebo and this tended to be lower in patients receiving the 2Á5-mg dose than in those receiving the 5-mg dose (1Á8% vs. 2Á4%, P = 0Á12) (Mega et al, 2012) . Other DOACS have also been evaluated in ACS but all have been associated with an increased bleeding risk when combined with DAPT and only a modest/non-statistically significant reduction in ischaemic events (Povsic et al, 2016) . Given the increase in bleeding seen with 'triple therapy', the GEMINI-ACS-1 study (NCT02293395) will evaluate 'dual antithrombotic therapy' i.e. rivaroxaban 2Á5 mg bd plus a P2Y12 inhibitor (clopidogrel or ticagrelor) versus DAPT (aspirin 100 mg od plus a P2Y12 inhibitor) (Povsic et al, 2016) .
Left ventricular thrombus
Left ventricular (LV) thrombus can complicate acute anterior MI, and the mainstay of evidence for using DOACs comes from numerous case reports (with their associated positive outcome reporting bias). LV thrombus resolution has been described with dabigatran (Nagamoto et al, 2014; Kolekar et al, 2015) , rivaroxaban (Nakasuka et al, 2014; Padilla Perez et al, 2014) and apixaban (Kaya et al, 2016; Mano et al, 2016) . Although there are no data in terms of randomised controlled trials to support DOAC use in this setting, the evidence for the commonly instituted alternative, VKA therapy, is less than compelling. In a 1993 meta-analysis of of patients who had an anterior MI, 7 studies were included (270 patients) that contained data on the relationship between anticoagulation for 6 months and embolisation but in only three trials did the trend of systemic anticoagulation reducing embolic complications reach significance. When pooling the data, anticoagulation compared with no anticoagulation was associated with a (not particularly convincing) reduction in the rate of embolization (OR 0Á14, 95% CI 0Á04-0Á52) and, unfortunately, no large randomised trials have been performed to evaluate the efficacy of longterm anticoagulation to prevent embolisation in patients with LV thrombus (Delewi et al, 2012) .
Treatment of VTE: grey areas
Cerebral venous thrombosis
According to British Committee for Standards in Haematology (BCSH) guidelines, patients with cerebral vein thrombosis (CVT) should be treated early with therapeutic-dose LMWH for at least 7 days followed by oral anticoagulation with warfarin (when the patient's condition has stabilised) for a suggested minimum of 3 months (Tait et al, 2012) . More recently published guidance concurs with this advice and also summarises the position with respect to DOACs: no CVT patients were enrolled in phase III clinical trials of the DOACs and one report of seven patients with CVT treated with rivaroxaban reported favourable outcomes. In the absence of clinical experience with DOAC use in CVT, there is no evidence for or against their use in clinical practice. The authors highlight that, although more evidence is needed before their use can be recommended, given the results of RCTs comparing DOACs with standard treatment in VTE, it seems plausible that the direct oral anticoagulants will have a role also in this setting .
Splanchnic vein thrombosis (SVT)
Guidelines recommend anticoagulation for a minimum of 3 months in all SVT patients and while anticoagulation can be discontinued in the presence of major transient risk factors (such as surgery or infections) for all other patients, including patients with cirrhosis, indefinite treatment should be considered . The risk of anticoagulation-related bleeding is high in patients with cirrhosis presenting with acute or chronic portal vein thrombosis (Tait et al, 2012) and screening for oesophageal varices as well as prophylactic variceal banding should be considered for all cirrhotic patients with SVT . DOACs are being used in patients with SVT and cirrhosis despite a lack of evidence. As with CVT, no SVT patients were included in phase III clinical trials of DOACs although a large case series has been published (De Gottardi et al, 2016) . Data were collected through the Vascular Liver Disease Interest Group Consortium for 94 patients from 17 centres. Thirty-six patients (38%) had cirrhosis. Indications for anticoagulation were SVT (75%), DVT (5%), AF (14%) and others (6%). DOACs used were rivaroxaban (83%), dabigatran (11%) and apixaban (6%). Patients were followed up for a median duration of 15 months (cirrhotic) and 26Á5 months (non-cirrhotic). Adverse events occurred in 17% of patients and included one case of recurrent portal vein thrombosis and five cases of bleeding (De Gottardi et al, 2016) . DOACs appear to be a safe and effective alternative to VKAs in SVT, but should be used with caution pending further clinical trials given both the increased risk of GI bleeding seen in some of the phase III DOAC trials and the hepatic (at least in part) metabolism of the DOACs. Randomised controlled trials are warranted to compare DOACs versus warfarin for SVT.
Treatment of VTE in cancer
DOACs offer an appealing alternative to injectable LMWH in the treatment of cancer. However, based on current evidence, LMWH remains the recommended initial treatment for cancer-associated VTE according to BCSH (and international) guidance (Watson et al, 2015) and has consistently demonstrated superiority over VKA treatment for VTE recurrence in the treatment of cancer-associated thrombosis, (Meyer et al, 2002; Lee et al, 2003 Lee et al, , 2015 Hull et al, 2006) . The DOAC VTE trials involved small numbers of patients with active cancer [5Á2% of total patients in EINSTEIN , 3Á1% in AMPLIFY (Agnelli et al, 2015) and 2Á5% in HOKUSAI-VTE (Hokusai et al, 2013) ]. Subgroup analysis suggests DOACs may have similar efficacy to warfarin but no direct comparisons with LMWH have been studied (van der Hulle et al, 2014) . The DOACs versus LMWH+/À Warfarin for VTE in Cancer (CANVAS) (NCT02744092) is currently recruiting participants and aims to determine the effectiveness of LMWH/ warfarin versus DOACs for preventing recurrent VTE in cancer patients. Patients will receive one of the four DOACs (edoxaban, apixaban, rivaroxaban, or dabigatran), LMWH alone, or warfarin (with LMWH bridging).
DOACs in antiphospholipid syndrome
Anticoagulation with VKAs is the mainstay of treatment of venous and/or arterial thromboembolism in patients with antiphospholipid syndrome (APS), although the optimal intensity of anticoagulation remains controversial (Cohen & Machin, 2010) . The DOACs would simplify treatment for patients with APS but their efficacy in APS remains uncertain. The RAPS (rivaroxaban versus warfarin to treat patients with thrombotic APS, with or without systemic lupus erythematosus) trial included APS patients on warfarin for previous VTE (with a target international normalised ratio of 2Á5) . 116 patients were randomly assigned 1:1 to continue with warfarin or receive 20 mg oral rivaroxaban daily. The primary outcome was percentage change in endogenous thrombin potential (ETP) from randomisation to day 42, with non-inferiority set at less than 20% difference from warfarin in mean percentage change. At day 42, ETP was higher in the rivaroxaban than in the warfarin group (geometric mean 1086 nmol/l per min, 95% CI 957-1233 vs. 548, 484-621, treatment effect 2Á0, 95% CI 1Á7-2Á4, P < 0Á0001) and ETP for rivaroxaban failed to reach the non-inferiority threshold , which suggests that APS patients on rivaroxaban may be at increased risk of thrombosis. The authors concluded that, as there was no increase in thrombotic risk compared with standard-intensity warfarin, rivaroxaban could be an effective and safe alternative in patients with APS and previous VTE . However, a recent systematic review of 122 APS patients treated with DOACs highlights the risk of thrombosis recurrence (which occurred in 15Á6%) and cautions against the use of DOACs in APS until randomised control trials with clinical primary endpoints can establish that DOACs have both efficacy and safety in this patient group compared to VKAs (Dufrost et al, 2016 ).
Women's health issues
Menstrual bleeding
The most suitable OAC has yet to be established for women of reproductive age, who can develop menorrhagia on anticoagulation. Several groups have reported heavy menstrual bleeding (HMB) on rivaroxaban with an incidence of between 20% and 25% (De Crem et al, 2015; Ferreira et al, 2016; Myers & Webster, 2017) . Data were gathered either from a questionnaire (De Crem et al, 2015) , registry data (Myers & Webster, 2017) or retrospective review of clinical notes (Ferreira et al, 2016) . These figures contrast starkly with those reported from published clinical trials, including a meta-analysis of trials evaluating bleeding on rivaroxaban therapy, which does not mention HMB (Wasserlauf et al, 2013) , indicating that these symptoms are likely to be under-reported by women in clinical trials. HMB may well be an effect shared by the Xa inhibitors (BeyerWestendorf et al, 2016) . Although fewer numbers of women received apixaban in the registry cohort reported by Myers et al (2016) , the incidence of HMB in those on apixaban was 9Á3%. Recent post-hoc analysis of the AMPLIFY trial (examining characteristics and treatment of vaginal bleeding in women with VTE treated with apixaban or enoxaparin followed by warfarin) suggested a low rate of clinically relevant major vaginal bleeding on apixaban (2Á5%) and compared favourably with those receiving enoxaparin/warfarin (2Á1%) (Brekelmans et al, 2017) , however, under-reporting here should be considered. HMB has been reported with dabigatran in a single case report (Winans & Ademolu, 2013) . It is likely that all anticoagulants worsen menstrual bleeding but which DOAC is least likely to exacerbate this remains unclear. Our experience at King's College Hospital has previously been described (Ferreira et al, 2016) .
Pregnancy and breastfeeding
Heparins neither cross the placenta nor are secreted in breast milk (Bauersachs, 2009) and are therefore safe during both pregnancy and breastfeeding. Warfarin is teratogenic and generally avoided in pregnancy but is safe to use during breastfeeding (Orme et al, 1977) . Pregnant and breastfeeding women were excluded from clinical trials evaluating DOACs and therefore, in lieu of safety and efficacy data, the SPCs for all the DOACs advise against use in pregnancy and breastfeeding.
Pregnancy
Animal studies have described toxic effects during pregnancy of rivaroxaban (including post-implantation pregnancy loss, increased malformations and placental changes), dabigatran (pre-implantation loss, low fetal body weight and viability) and edoxaban (gall bladder variations and post-implantation loss) (Myers et al, 2016) . Interestingly, animal studies with apixaban did not indicate direct or indirect harmful effects with respect to reproductive toxicity (https://www.medicines. org.uk/emc/medicine/27223).
In humans, the DOACs have been demonstrated to pass through the placenta from mother to fetus. A study examining rivaroxaban transfer using a dually perfused isolated human placenta model demonstrated that rivaroxaban could cross the placenta in both maternal-to-fetal and fetal-maternal directions (Bapat et al, 2015) . The authors acknowledge some of the limitations of this model: only full-term placentae were used (so the results cannot be extrapolated to earlier gestational ages when placental structure is different), and non-placental PK factors (such as protein binding and clearance rate) were not accounted for. Rivaroxaban is highly protein-bound (to serum albumin in the maternal circulation) and, as such, the fetal exposure to rivaroxaban is predicted to be less than that shown in this perfusion model (Bapat et al, 2015) . It is likely, therefore, that rivaroxaban enters the fetal circulation but whether in significant amounts or if sufficient to negatively affect the developing human embryo or fetus remains unclear. Using the abovementioned model, the same group has demonstrated that dabigatran and dabigatran etexilate mesylate both cross the human placenta from mother to fetus (Bapat et al, 2014) , as does apixaban (Bapat et al, 2016) .
There are 2 published case reports describing the delivery of healthy infants following exposure to rivaroxaban during pregnancy (Konigsbrugge et al, 2014; Myers et al, 2016) al, 2016) . The duration of exposure was heterogeneous (but largely limited to the first trimester). Out of 63 pregnancies exposed to rivaroxaban, 37 were prospectively ascertained and resulted in 23 live births (plus 6 miscarriages and 8 terminations). There was one major malformation (conotruncal cardiac defect) in a woman with complex medication and a previous fetus with cardiac malformation without exposure to rivaroxaban (Hoeltzenbein et al, 2016) . Ten patients became pregnant during the edoxaban VTE study with exposure occurring in the first trimester and lasting about 6 weeks; there were six live births (two pre-term), one first trimester miscarriage and three elective terminations (Myers et al, 2016) .
To assess the risk of DOAC embryopathy, a recent review examined cases of DOAC exposure in pregnancy collected from physicians, literature and pharmacovigilance systems of drug authorities and manufacturers . Their findings do not suggest that DOAC exposure in pregnancy carries a high risk of embryopathy, however, 2Á2% of 137 pregnancies with reported outcomes had defects that could potentially be interpreted as embryopathy and the authors acknowledge that pregnancy outcomes are inconsistently captured in pharmacovigilance databases .
Breastfeeding
The safety of DOACs and breastfeeding has not been determined and all DOACs should currently be avoided in this scenario. A recent case report suggests rivaroxaban is secreted in human breast milk. Rivaroxaban concentrations determined by liquid chromatography tandem-mass spectrometry from breast milk samples were detected in human breast milk in comparatively small amounts (Wiesen et al, 2016) . Data from rats confirm that after single oral doses of [ (14)C] apixaban, lactating rats exhibited extensive secretion into rat milk with the parent drug as the major component (Wang et al, 2011) . Data from humans is not currently available. Animal data suggest that edoxaban is secreted into breast milk (https://www.medicines.org.uk/emc/medicine/30506) but human data is not available. It is unknown whether dabigatran is secreted in breast milk.
Drug monitoring and adherence
The DOACs have been licensed worldwide without the need for routine laboratory monitoring based on the landmark phase III clinical trials , although it is well recognised that the clinical trial populations do not reflect patients we face in the real-world. The debate relating to whether these drugs should be monitored is outside the scope of this review, but there are specific circumstances where measuring DOAC concentration may be desired. These include: extremes of body weight, the presence of concomitant interacting drugs, significant renal or liver dysfunction and to confirm absorption (Kitchen et al, 2014) . Therapeutic ranges for which clinical outcomes are optimised are yet to be defined (Samuelson & Cuker, 2017) but 'expected' drug levels are provided in guidance from the BCSH (Kitchen et al, 2014) , the relevant drug's SPC, and from additional data summarised in published reviews specifically examining DOAC measurement (Samuelson & Cuker, 2017) .
In terms of adherence, although the DOACs have many practical advantages both from a patient and clinician perspective, there is concern that, when prescribed for patients long-term, adherence may become sub-optimal relative to VKA therapy, particularly as there is no regular follow-up required in a clinic setting. We refer interested readers to a comprehensive review on this specific topic by our group published last year (Abdou et al, 2016) .
DOACs and the future
A fifth DOAC is currently under evaluation, the direct Xa inhibitor betrixaban (Palladino et al, 2013) . Betrixaban does possess some unique features, which clinically may differentiate it from the other DOACs. Chief amongst these is limited renal excretion (<8% of the orally administered betrixaban is renally excreted). As the results from clinical trials of betrixaban are published, it will only be a matter of time, before this additional option will be available to prescribers.
At the time of writing, a search on clinicaltrials.gov reveals that a number of studies are being conducted within the paediatric population (Table III) . Whilst the use of anticoagulant therapy in the paediatric setting is not substantial, there would of course be clear advantages for the patients in question, if DOACs could be prescribed in place of traditional anticoagulants. It is likely these agents will be available to paediatric patients, when indicated, once dosing and safety matters are resolved.
DOACs are appealing for treatment of heparin-induced thrombocytopenia (HIT), particularly for stable patients who do not have invasive procedures planned. There are numerous case reports where DOACs have successfully been used in the treatment of HIT, with rivaroxaban being the most studied DOAC for this indication, and it has recently been evaluated in a Canadian multicentre, single-arm, prospective cohort study of patients with suspected or confirmed HIT (Linkins et al, 2016) . Twenty-two consecutive patients received rivaroxaban 15 mg bd until a local HIT assay result was available. Those with a positive local assay result continued rivaroxaban 15 mg bd until platelet recovery (or until day 21 if they had acute thrombosis at study entry), then stepped down to rivaroxaban 20 mg daily until day 30. Twelve patients were HIT-positive and 6 had HIT with thrombosis (HITT). The primary outcome measure, incidence of new symptomatic, objectively-confirmed venous and arterial thromboembolism at 30 days, occurred in one HIT-positive participant and one HIT-positive participant required limb amputation despite platelet recovery. Platelet recovery was achieved in nine out of 10 HIT-positive patients with thrombocytopenia. Rivaroxaban appears to be effective for treating patients with confirmed HIT although the sample size was small (Linkins et al, 2016) . Experience with using DOACs off-label in this setting is likely to increase in the future. For the past 50 years or so, the clinical community have enjoyed having a single OAC predominantly being prescribed in the UK, and worldwide having a single test for all VKAs that all clinicians can interpret. The DOACs have brought two new risks with their arrival; unfamiliarity of the agents themselves and what impact these DOACs have on common tests of haemostasis. A recently published UK study (Olaiya et al, 2016) reports that the level of awareness of different DOACs was relatively poor, with many clinicians not recognising that a hypothetical patient they were challenged with, being anticoagulated with a DOAC based on the laboratory results provided to them. One might anticipate this lack of awareness issue to decrease with widespread DOAC use, however the impact of DOACs on the common tests of haemostasis might be more of a challenge to overcome, as not only do the Xa inhibitors and dabigatran have differing effects on these tests (Kitchen et al, 2014) , within the Xa inhibitor class the effects differ from agent to agent but are also dependent on which reagent is utilised (Kitchen et al, 2014) . Therefore a clinician working in one hospital, where the prothrombin reagent used is sensitive to rivaroxaban, e.g. Neoplastin CI+ â , may rotate to a hospital, where the prothrombin time reagent used is Innovin â and is not as sensitive and if they are unaware of such nuances with reagent changes, they may interpret a prothombin time result inappropriately in the context of rivaroxaban use, for example. Those charged with overseeing anticoagulation services, particularly in the secondary care setting, should be mindful of this and until the wider medical community have increased awareness. Ongoing education efforts should be maintained around increasing the awareness of these agents and the impact the agents have on their tests locally.
With the distinct properties that each DOAC possess, ideally, the future would see head-to-head studies of the DOACs to truly understand if one DOAC is better than another. Such studies rarely take place and are unlikely to take place in the foreseeable future. In the meantime, real-world, prospective cohort studies will provide ongoing valuable information on the optimal use of these agents in our patients.
Conclusions
The development and introduction of DOACs represents a huge advancement in the field of anticoagulation. DOACs have proven efficacy in a variety of indications and have increased accessibility to anticoagulation. The obvious appeal of OACs that do not require monitoring or parenteral bridging naturally means that clinical scenarios in which VKAs or LMWH would traditionally be used are now considered as potential avenues for DOACs and there are a number of scenarios where the efficacy of DOACs compared with traditional anticoagulants remains to be determined. A number of trials are currently underway to expand indications for DOAC use. In clinical conditions where it is unlikely that randomised trials can be successfully completed, data should be collected from prospective cohort studies.
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